Insiders · RANI

RANI insider transactions

Rani Therapeutics Holdings Inc. (RANI) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

RANI insiders

Everyone who has filed a Form 3, 4, 5 or 144 at Rani Therapeutics Holdings Inc., latest first. Follow anyone to get their next filing.

• Talat ImranChief Executive Officer, Director+$132K-$11.3K
• Alireza JavadiChief Technical Officer, since March 2026-$301
• Michelle GilsonDirector, since August 2026
• Mir A ImranDirector, 10% owner+$1.29M-$854K
• Nicholas MaestasChief Financial Officer, since June 2026
• Kate McKinleyChief Business Officer+$30K
• Abraham BassanDirector, since October 2025
• Lisa Ann RomettyDirector, since January 2022
• Jean Luc ButelDirector+$102K
• Vasudev Jaiprakash BaileyDirector, since October 2025
• Dennis A AusielloDirector
• South Cone Investments Limited Partnership10% owner+$12.7M-$25.9M
• Maulik NanavatyDirector+$990
• Andrew FarquharsonDirector-$854K
• Mir HashimChief Scientific Officer
• Svai S SanfordChief Financial Officer
• Laureen DebuonoDirector
• Eric GroenGeneral Counsel, since March 2022
• Quiroga Cortes Isidoro Alfonso10% owner+$720K-$10.6M
• Lyn BaranowskiDirector, since November 2021
• InCube Labs, L.L.C.10% owner

Recent Form 3, 4, and 5 filings for RANI

• 40d
  Chief Executive Officer Imran Talat covered exercise/tax liability with 7,928 shares, decreasing direct ownership by 2% to 461,808 units (SEC Form 4) to satisfy withholding obligation

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 40d
  Chief Technical Officer Javadi Alireza covered exercise/tax liability with 309 shares, decreasing direct ownership by 3% to 9,071 units (SEC Form 4) (for tax liability)

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 95d
  SEC Form 4 filed by Director Gilson Michelle

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 95d
  SEC Form 3 filed by new insider Gilson Michelle

  3 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 108d
  Director Imran Mir A bought $24,840 worth of shares (36,000 units at $0.69), increasing direct ownership by 2% to 2,119,334 units (SEC Form 4)

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 109d
  Chief Technical Officer Javadi Alireza sold $301 worth of shares (386 units at $0.78) and covered exercise/tax liability with 309 shares, decreasing direct ownership by 7% to 9,380 units (SEC Form 4) (withholding obligation)

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 110d
  Chief Executive Officer Imran Talat bought $25,193 worth of shares (35,000 units at $0.72), increasing direct ownership by 8% to 469,736 units (SEC Form 4)

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 110d
  Chief Executive Officer Imran Talat sold $11,300 worth of shares (8,014 units at $1.41) and covered exercise/tax liability with 52,001 shares, decreasing direct ownership by 12% to 434,736 units (SEC Form 4) (withholding obligation)

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 110d
  SEC Form 4 filed by Chief Financial Officer Maestas Nicholas

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 123d
  SEC Form 3 filed by new insider Maestas Nicholas

  3 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 156d
  SEC Form 4 filed by Chief Business Officer Mckinley Kate

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 156d
  SEC Form 4 filed by Chief Technical Officer Javadi Alireza

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 156d
  SEC Form 4 filed by Chief Executive Officer Imran Talat

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 160d
  SEC Form 4 filed by Director Bassan Abraham

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 160d
  SEC Form 4 filed by Director Rometty Lisa Ann

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 160d
  SEC Form 4 filed by Director Imran Mir A

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 160d
  SEC Form 4 filed by Director Butel Jean Luc

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 160d
  SEC Form 4 filed by Director Bailey Vasudev Jaiprakash

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 160d
  SEC Form 4 filed by Director Ausiello Dennis A

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 225d
  SEC Form 3 filed by new insider Javadi Alireza

  3 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 374d
  SEC Form 4 filed by Director Bailey Vasudev Jaiprakash

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 374d
  SEC Form 3 filed by new insider Bailey Vasudev Jaiprakash

  3 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 376d
  SEC Form 4 filed by Director Bassan Abraham

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 376d
  SEC Form 3 filed by new insider Bassan Abraham

  3 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 376d
  Director Imran Mir A bought $1,260,417 worth of shares (2,083,334 units at $0.60) (SEC Form 4)

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 382d
  Large owner South Cone Investments Limited Partnership sold $15,711,314 worth of shares (5,923,000 units at $2.65) (SEC Form 4)

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 460d
  SEC Form 4 filed by Chief Business Officer Mckinley Kate

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 527d
  SEC Form 4 filed by Director Nanavaty Maulik

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 527d
  SEC Form 4 filed by Director Imran Mir A

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 527d
  SEC Form 4 filed by Director Rometty Lisa Ann

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 527d
  SEC Form 4 filed by Director Butel Jean Luc

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 527d
  SEC Form 4 filed by Director Ausiello Dennis A

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 527d
  SEC Form 4 filed by Director Farquharson Andrew

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 534d
  SEC Form 4 filed by Chief Scientific Officer Hashim Mir

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 534d
  SEC Form 4 filed by Chief Business Officer Mckinley Kate

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 534d
  SEC Form 4 filed by Chief Executive Officer Imran Talat

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 534d
  SEC Form 4 filed by Chief Financial Officer Sanford Svai S

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 691d
  SEC Form 4 filed by Director Rometty Lisa Ann

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 691d
  SEC Form 4 filed by Director Debuono Laureen

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 691d
  SEC Form 4 filed by Director Farquharson Andrew

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 691d
  SEC Form 4 filed by Director Ausiello Dennis A

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 691d
  SEC Form 4 filed by Director Butel Jean Luc

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 691d
  SEC Form 4 filed by Director Imran Mir A

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 691d
  SEC Form 4 filed by Director Nanavaty Maulik

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 692d
  Chief Business Officer Mckinley Kate bought $29,993 worth of shares (17,960 units at $1.67) (SEC Form 4)

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 698d
  Chief Executive Officer Imran Talat bought $19,974 worth of shares (10,296 units at $1.94), increasing direct ownership by 2% to 494,751 units (SEC Form 4)

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 752d
  Large owner South Cone Investments Limited Partnership sold $10,141,674 worth of shares (3,829,360 units at $2.65) (SEC Form 4)

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 892d
  SEC Form 4 filed by Imran Mir A

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 892d
  SEC Form 4 filed by Butel Jean Luc

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 892d
  SEC Form 4 filed by Rometty Lisa Ann

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 892d
  SEC Form 4 filed by Debuono Laureen

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 892d
  SEC Form 4 filed by Nanavaty Maulik

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 892d
  SEC Form 4 filed by Farquharson Andrew

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 892d
  SEC Form 4 filed by Ausiello Dennis A

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 960d
  SEC Form 4 filed by Mckinley Kate

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 960d
  SEC Form 4 filed by Hashim Mir

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 960d
  SEC Form 4 filed by Groen Eric

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 960d
  SEC Form 4 filed by Imran Talat

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 960d
  SEC Form 4 filed by Sanford Svai S

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
• 1055d
  SEC Form 4 filed by Hashim Mir

  4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)